Bristol Myers Squibb Co (BMY) Interest Expenses (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Interest Expenses for 18 consecutive years, with $407.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Interest Expenses fell 16.08% year-over-year to $407.0 million; the TTM figure through Jun 2026 stood at $1.8 billion (down 16.59% YoY), while the FY2025 annual figure was $2.6 billion, up 31.95% from the prior year.
• Interest Expenses slipped to $407.0 million in Q2 2026 per BMY's latest filing, from $473.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $624.0 million in Q1 2025 and bottomed at $268.0 million in Q4 2023.
• Historically, Interest Expenses has averaged $403.3 million across 5 years, with a median of $403.5 million in 2025.
• Annual changes were most pronounced in 2024 — Interest Expenses soared 85.07% — and 2026, when it slipped 24.2%.
• Bristol Myers Squibb's Interest Expenses stood at $300.0 million in 2022, then dropped by 10.67% to $268.0 million in 2023, then jumped by 85.07% to $496.0 million in 2024, then retreated by 19.35% to $400.0 million in 2025, then advanced by 1.75% to $407.0 million in 2026.
• Business Quant data shows BMY's Interest Expenses at $407.0 million in Q2 2026, $473.0 million in Q1 2026, and $400.0 million in Q4 2025.